Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy
Minlin Jiang, Keyi Jia, Lei Wang, et al.
Acta Pharmaceutica Sinica B (2021) Vol. 11, Iss. 10, pp. 2983-2994
Open Access | Times Cited: 202

Showing 1-25 of 202 citing articles:

FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients
Ye Wang, Zhuang Tong, Wen‐Hua Zhang, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 147
Immune Checkpoint Inhibitors Combined with Targeted Therapy: The Recent Advances and Future Potentials
Bin Li, Juan Jin, Duancheng Guo, et al.
Cancers (2023) Vol. 15, Iss. 10, pp. 2858-2858
Open Access | Times Cited: 53
Functional Endophytes Regulating Plant Secondary Metabolism: Current Status, Prospects and Applications
Zhaogao Li, Keyi Xiong, Weie Wen, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 1153-1153
Open Access | Times Cited: 50
Unboxing the molecular modalities of mutagens in cancer
Smita Kumari, Sudhanshu Sharma, Dia Advani, et al.
Environmental Science and Pollution Research (2021) Vol. 29, Iss. 41, pp. 62111-62159
Open Access | Times Cited: 73
Small molecule-based immunomodulators for cancer therapy
Yinrong Wu, Zichao Yang, Kui Cheng, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 12, Iss. 12, pp. 4287-4308
Open Access | Times Cited: 65
Ferredoxin 1 is a cuproptosis-key gene responsible for tumor immunity and drug sensitivity: A pan-cancer analysis
Longfei Yang, Yuwei Zhang, Yang Wang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 49
The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy
Congqi Shi, Kaiyu Qin, Anqi Lin, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 41
Histone deacetylase-mediated tumor microenvironment characteristics and synergistic immunotherapy in gastric cancer
Yilin Lin, Xiangxiang Jing, Zhihua Chen, et al.
Theranostics (2023) Vol. 13, Iss. 13, pp. 4574-4600
Open Access | Times Cited: 27
Identification and integration analysis of a novel prognostic signature associated with cuproptosis-related ferroptosis genes and relevant lncRNA regulatory axis in lung adenocarcinoma
Tianyue Wang, Xinyu Jiang, Ying Lü, et al.
Aging (2023)
Open Access | Times Cited: 26
MyD88 and Its Inhibitors in Cancer: Prospects and Challenges
Jiali Song, Yuying Li, Ke Wu, et al.
Biomolecules (2024) Vol. 14, Iss. 5, pp. 562-562
Open Access | Times Cited: 8
STING in Cancer Immunoediting: Modeling Tumor-Immune Dynamics Throughout Cancer Development
Xiao Zhang, Yan Chen, Xi Liu, et al.
Cancer Letters (2025) Vol. 612, pp. 217410-217410
Open Access | Times Cited: 1
Parps in immune response: Potential targets for cancer immunotherapy
S Wang, Jingling Huang, T. X. Zeng, et al.
Biochemical Pharmacology (2025) Vol. 234, pp. 116803-116803
Closed Access | Times Cited: 1
Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer
Fabio Catalano, Roberto Borea, Silvia Puglisi, et al.
Cancers (2022) Vol. 14, Iss. 6, pp. 1388-1388
Open Access | Times Cited: 33
Genomic and transcriptomic profiling indicates the prognosis significance of mutational signature for TMB-high subtype in Chinese patients with gastric cancer
Yanan Cheng, Dechao Bu, Qiaoling Zhang, et al.
Journal of Advanced Research (2022) Vol. 51, pp. 121-134
Open Access | Times Cited: 28
Non-canonical STING–PERK pathway dependent epigenetic regulation of vascular endothelial dysfunction via integrating IRF3 and NF-κB in inflammatory response
Xuesong Li, Xiang Chen, Longbin Zheng, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 12, pp. 4765-4784
Open Access | Times Cited: 20
Insights into DNMT1 and programmed cell death in diseases
Lan Yan, Qi Geng, Zhiwen Cao, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 168, pp. 115753-115753
Open Access | Times Cited: 18
Targeted therapy and immunotherapy: Diamonds in the rough in the treatment of epithelial ovarian cancer
Xu Huang, Xiaoyu Li, Wulin Shan, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 17
DNA replication: Mechanisms and therapeutic interventions for diseases
Haoyun Song, Rong Shen, Mahasin Abdallah Mohammed Hamid, et al.
MedComm (2023) Vol. 4, Iss. 1
Open Access | Times Cited: 16
DNA damage response in breast cancer and its significant role in guiding novel precise therapies
Jiayi Li, Ziqi Jia, Dong Lin, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 7
Guanosine diphosphate–mannose suppresses homologous recombination repair and potentiates antitumor immunity in triple-negative breast cancer
Jia-Han Ding, Yi Xiao, Fan Yang, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 728
Closed Access | Times Cited: 6
Total Neoadjuvant Therapy With PD-1 Blockade for High-Risk Proficient Mismatch Repair Rectal Cancer
Yingjie Li, Chaohu Pan, Yuye Gao, et al.
JAMA Surgery (2024) Vol. 159, Iss. 5, pp. 529-529
Closed Access | Times Cited: 6
Patterns and trends in melanoma mortality in the United States, 1999–2020
Alexander J. Didier, Swamroop Nandwani, Dean Watkins, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 6
Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy
Chang‐Shen Lin, Yu‐Tzu Chang, Zhen-Yang Hong, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 6, pp. 3238-3238
Open Access | Times Cited: 25
Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy
Xiaopeng Peng, Wanyi Pan, Feng Jiang, et al.
Pharmacological Research (2022) Vol. 186, pp. 106529-106529
Closed Access | Times Cited: 22
SWI/SNF complex gene variations are associated with a higher tumor mutational burden and a better response to immune checkpoint inhibitor treatment: a pan-cancer analysis of next-generation sequencing data corresponding to 4591 cases
Yue Li, Xinhua Yang, Weijie Zhu, et al.
Cancer Cell International (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 22
Page 1 - Next Page

Scroll to top